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Abstract
Objectives: To examine the feasibility of three-dimensional computed tomography (3D-CT) image fusion
in facilitating assessment of the ablative margin (AM) after radiofrequency ablation (RFA) of hepatocellular
carcinoma (HCC).
Methods: This study involved 75 patients with solitary HCC who underwent RFA. The AM was evaluated
using 3D-CT image fusion. All cases were categorized into two groups based on the extent of the AM: in
Group A, sufficient AM was obtained, which was greater than or equal to 5 mm; in Group B, the lesion was
also ablated successfully, but a 5 mm AM was not obtained.
Results: 3D-CT Image Fusion was performed on 36 and 39 patients in Group A and Group B, respec-
tively. The 1, 3, 5 year RFS was 87.6%, 63.2%, 50.6% for Group A, and 77.2%, 51.5%, 35.6% for Group
B, respectively (P = 0.042); the corresponding OS was 94.3%, 73.8%, 64.6%, and 86.2%, 60.5%, 47.6%,
respectively (P = 0.046). Multivariate analysis showed that the AM (P = 0.048, HR = 2.15, 95% CI
1.01–4.60) and Pre-NLR were independent prognostic factors for PFS.
Conclusions: 3D-CT image fusion is a feasible and useful method to evaluate the AM after RFA of HCC.
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Introduction
Accurate knowledge of the anatomy of hepatic vessels and the
lesion is indispensable for safe liver surgery, including hepatec-
tomy and liver transplantation. This may also improve the success
rate of radiofrequency ablation (RFA). Three-dimensional com-
puted tomography (3D-CT) reconstruction enables visualization
of the hepatic vessels and helps the surgeon to perform hepatic
resections virtually under realistic anatomical conditions using a
software system.1 However, the application of 3D-CT reconstruc-
tion for RFA is not available.
RFA has been widely used as a representative of local therapy
for HCC.2 It plays an important role in the comprehensive treat-
ment of hepatocellular carcinoma (HCC); however, the heteroge-
neity of HCC patients still remains a challenge, and tumour
recurrence rates are still at a high level and difficult to control.3,4
Several previous studies have reported the association between the
ablative margin (AM) and local tumour progression (LTP) in
which insufficient AM may result in LTP.3–5 Thus, it is one of the
most significant factors to measure the AM for predicting LTP
after RFA.3,6 However, unlike surgical resection, assessing the area
of ablation accurately is difficult. Currently, none of the routine
imaging methods, including contrast-enhanced CT, magnetic
resonance (MR) or contrast-enhanced ultrasound (CEUS), can
accurately determine whether sufficient AM has been achieved.
Thus, a reliable and simple method is needed to estimate the AM.
Recently, new methods were used to evaluate the AM. Akiko
Tomonari et al.7 obtained contrast-enhanced CT before and after
RFA to generate an image fusion on a workstation. The AM of 12
patients were assessed using axial images. In all lesions, LTP was
congruent with the area of the thinnest AM. Fused imaging evalu-
ation had proven to be an accurate and effective tool for the
assessment of RFA margins. Zhong-Zhen et al.8 evaluated the AM
using 3D-CEUS-CT/MR image fusion after RFA of HCC. This
study consisted of a navigation system and a dynamic positioning
system,which combined ultrasound (US) with CT/MR, that could
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determine whether the AM around the lesion was successfully
covered using the two overlapped fused images. There are other
methods used to estimate the AM with MRI.9–11 Currently, image
fusion is studied in the two-dimensional structure. However,
because the intrahepatic vasculature is complex and varied, it is
difficult to intuitively distinguish the relationships between the
lesions and surrounding tissue. Thus, the emergence of 3D-CT
reconstruction may contribute to resolving this issue.
The purpose of this study was to investigate the feasibility of
3D-CT image fusion in facilitating the assessment of the AM after
RFA. Volume and recurrence factors were assessed. The effect of
different AMs on the 5-year overall survival (OS) and progression-
free survival (PFS) were analysed using this new method.
Patients and methods
From January 2008 to December 2012, 75 patients who under-
went percutaneous RFA under US at the Cancer Center of Guang-
zhou Medical University were included in the study. Within these
patients, single or overlapped multiple punctures were imple-
mented to ensure sufficient AM. The data images were collected
using a 64-slice helical CT (GE 64; AW4.4 Systems, GE Company,
Fairfield, CA, USA), and analysis was performed on a AW4.4 work
station. All patients were placed in the supine position and their
position was adjusted by raising their arms, and the scanning
range from the diaphragm to the kidney. The contract agent was a
high concentration of Ultravist 370, with the following scanning
parameters: current 250 mA and voltage 120 kV, thickness of
5 mm, 0.984 pitch, and rotation speed of 0.5 s/cycle. Scanning was
delayed 20 to 25 s after the arterial phase and 55 to 60 s after the
venous phase. Next, CT data of the arterial and venous phases, as
well as the portal vein phase, were transferred to the AW4.4 work-
station.Next, we used DVD rw as the intermediate, and copied the
data onto the DVD, and subsequently analysed the data using the
Myrian system (Intrasense SAS, Montpelier, France).
An artificial pleural effusion was performed if the lesion was
close to the hepatic dome. This method was successfully per-
formed if treatment-related death did not occur. Transcatheter
arterial chemoembolization (TACE) or RFA was performed in the
case of neoplasm recurrence.
All of our patients met the following criteria: Child–Pugh A or
B; absence of vascular invasion; tumour diameter less than 5 cm;
and pre- and post-operative CT (a month after RFA) images were
obtained. Many patients underwent the first contrast-enhanced
CT in other hospitals, and we could not acquire the CT data.
These patients were not included in this study. The exclusion
criteria were the following: loss to follow-up within 3months after
RFA; obstructive jaundice; Child–Pugh C; any other malignancy;
and cases where the anatomical structure around the ablation
zone was obviously changed, for example, massive ascites, which
may affect the original lesion position. In addition, three failed
RFA and one failed image fusion data were excluded. All study
participants provided their informed consent.
Tumour recurrence was diagnosed based on contrast-enhanced
CT and/or MRI. Needle biopsies of recurrent tumours were not
performed. A recurrent tumour was defined as a new enhancing
mass in the arterial phase with washout in the portal site or a
delayed phase of dynamic liver CT. If the mass had shown an
arterial enhancement without washout, then we used the interval
growth of the mass on follow-up imaging or lipiodol retention of
the tumour after TACE to confirm recurrent HCC.
Radiofrequency ablation procedure
The percutaneous RFA procedure was performed under real-time
US (SSD-ALPHA5, Hitachi Medical Systems, Prosound, fre-
quency: 3.5–5.0 MHZ, Hitachi Aloka Medical, Ltd., Tokyo, Japan)
guidance.We used a commercially available system (Cool-Tip, RF
Ablation System; Covidien, Shanghai, China) and a needle elec-
trode with a diameter of 3.5 cm at expansion. All patients were
placed in the supine position.RFA can be performed under local or
general anaesthesia, which was dependent on the actual situations
and the preferences of the examiner and surgeon. Before piercing,
we incised the skinwith a small lancet, and selected the appropriate
angle. We usually made the needle priority go through the liver
parenchyma and then through the lesions. The patients were
closely monitored during the procedure. During RFA, a
hyperechoic area was observed around the electrode tip using
ultrasonicmonitoring.The aimof the treatmentwas to ensure that
the area covering the lesions was larger than 0.5 cm. At the end of
the RFA, the generator was reactivated to ablate the needle tract to
prevent needle metastasis and bleeding.
3D CT reconstruction
Operation planning using 3D-CT image fusion software consisted
of the following steps: (i) import the pre- and post-operative CT
images of the DICOM format to the Myrian software system; (2)
reconstruct the liver structures (liver parenchyma, lesions, portal
vein, hepatic veins and hepatic artery) in a 3D model; (3) 3D-CT
image fusion; and (4) evaluate whether the ablation was successful
and measure the AM.
First, enhanced CT (portal venous phase series with slice thick-
ness of 1 mm) could clearly describe the selection. The CT data in
the DICOM format were transferred into the Myrian-Xp-Live
system, which could segment the liver in the semi-automatic
mode.When the operator selected the liver parenchyma in a two-
dimensional CT in a scanning level, the Myrian system automati-
cally generated the 3D data and displayed the reconstructed 3D
images of the liver in planes on the screen, as the density of some
organizations (such as heart andmuscle) did not appear to be very
different. The region of identification could be excessive or insuf-
ficient, and thus, proper cutting should be manually performed.
Next, the portal vein, hepatic veins and hepatic artery were also
reconstructed in the same manner. The lesion density was gener-
ally low and an irregular shape, and thus, automatic identification
was not sufficiently precise; we usually outlined the lesion edge of
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0.5 cm spacing manually, then clicked on the ‘stretch’ button and
finished the lesion 3D reconstruction. If possible, the spleen and
pancreas were included. The relationship between the lesion
and vascular system was confirmed almost instantaneous from
any angle. Introduction of the 3D-CT reconstruction software had
deepened our understanding of liver anatomy.12,13 Post-operative
CT data were reconstructed in the same manner. The ablative
extent covers the entire lesion in all directions, and more than
5 mm AM was better. Although this was ideal, it was not easy to
attain the 5 mm AM in some situations owing to adjacent vessels,
intestines or gallbladder and respiratory motion.
3D CT image fusion
Standardized dual-phase contrast-enhanced spiral CT scanning
was performed in all patients, prior to image fusion, and pre- and
post-operative CT were reconstructed. Registration was a process
of matching two or more image volumes based on their content;
these volumes had the same or different dimensions, but repre-
sented the same body area, and could be synchronously navigated
or displayed on top of the other fusion.
The registration dataset image fusion is used to synchronize the
anatomical centre between the image volumes which have been
registered such that placing the anatomical centre on an object of
interest (such as a nodule) in one series will move the anatomical
centre to the same object of interest in the other series. The region
of interest (ROI) is deformed between series (for instance in a
multiphase liver acquisition) to superimpose the ROI from
various phases while correcting patient movements or breathing
displacement. After registration and fine adjustment, it would
enable a more precise fusion until the two images are brought into
spatial alignment.
After registration, the image of the ablation zone and lesion
were superimposed in a 3D image, to estimate whether the abla-
tion zone successfully covered the lesion in all directions by
adjusting the transparency. Using the 360-degree rotation, we
determined the thinnest AM and measured it, which was different
from two-dimensional CT (it usually measures the AM in a single
plane). 3D-CT images makes it more simple and visualized.
Statistical analysis
All measurement data were expressed as the mean ± standard
deviation and were analysed using SPSS 13.0 statistics software
(SPSS Company, Chicago, IL, USA). The total liver volume was
estimated using the 3D-CT reconstruction system. The recurrence
and overall free survivals were calculated using Kaplan–Meier
analysis. The survival curves were constructed using Kaplan–
Meier analysis and compared using the log-rank test. We used
multivariate Cox proportional hazards regression analysis to
predict the prognostic varieties of recurrence-free survival. All of
the statistical tests were two-sided, and P-levels < 0.05 was con-
sidered statistically significant.
Results
From January 2008 to December 2012, 141 patients with a small
liver tumour underwent RFA in the Department of Hepatobiliary
Surgery, Cancer Center of Guangzhou Medical University. On the
basis of our inclusion criteria, 66 patients were excluded from this
study. Among these patients, 21 patients lost their CT dates, 16
patients exhibited recurrence after a hepatic resection, 12 patients
received TACE before RFA and 7 patients had liver metastasis. In
addition, 6 patients were lost to follow-up within 3 months after
RFA, 3 patients failed the RFA (due to large vessels close to the
lesions, which indicated that the RFA failed the second time RFA
or TACEwas performed) and 1 patient failed the image fusion and
was excluded. Finally, 75 patients met all of our inclusion criteria
and were enrolled in this study.
There were 75 patients [59 males and 16 females; ages 33–79
years (55.9 ± 10.4)]. The lesion diameters ranged from 8 to
41 mm, with a mean of (24.0 ± 7) mm. The mean liver volume
calculated using the 3D reconstruction system was 1192 ± 277 ml
(Table 1).
As shown in Table 2, univariate analysis revealed that the
recurrence-free survival was directly affected by the AFP, ALB,
pre-operative NLR and AM change. Multivariate analysis showed
that pre-operative NLR [P = 0.026, hazard ratio (HR) = 2.34; 95%
confidence interval (CI) 1.11–5.12], AM change (P = 0.048, HR =
Table 1 Baseline characteristics of the 75 patients with hepatocel-
lular carcinoma (HCC)
Clinical characteristics Number of patients
or mean ± SD
Gender
Male/ Female 59/16
Age (year) 55.9 ± 10.4
Hepatitis B
Yes/No 64/11
Child–Pugh class
A/ B 68/7
AFP level, ng/ml
≤400/>400 23/52
Close to vessels
Yes/ No 19/56
Tumour size, mm, 24.0 ± 7
AST (u/l) 44.3 ± 19.4
ALT(u/l) 44.9 ± 29.4
ALB(g/l) 40.5 ± 4.5
GGT(u/l) 77.8 ± 35.2
TBIL(umol/l) 19.4 ± 14.7
Tumour volume (ml) 1192 ± 277 (673–2187)
AFP, alpha-fetoprotein; AST, aspartate aminotransferase; ALT, alanine
transaminase. ALB, serum albumin; GGT, gamma glutamyl
transpeptidase; TBIL, total bilirubin.
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2.15; 95% CI 1.01–4.60) were significant prognostic factors for
recurrence-free survival after RFA.
These results were categorized into two groups: Group A (36
patients): the ablation zone in the 3D-CT image covered the lesion
and attained 5 mm AM, which indicated that the lesion was com-
pletely ablated and sufficient AM was obtained (Fig. 1); Group B
(39 patients): the ablation zone in the 3D-CT image covered the
lesion but did not attain 5 mm AM, indicating that the lesion was
completely ablated, but sufficient AM was not obtained (Fig. 2).
To evaluate the role of 3D-CT image fusion in the treatment of
liver lesions with RFA,we compared the prognosis between Group
A and Group B. The 1, 3, 5 years RFS were 87.6%, 63.2%, 50.6%
for Group A, and 77.2%, 51.5%, 35.6% for Group B, respectively
(P = 0.042); the corresponding OS was 94.3%, 73.8%, 64.6%, and
Table 2 COX analyses contributing to progression-free survival (PFS) after initial radiofrequency ablation (RFA) for all cases (n = 75)
Variables Univariate Multivariate
Hazard radio (95%CI) P-value Hazard radio (95%CI) P-value
Age(years)
0.95 (0.43–2.13) 0.908≥50
<50
Gender
3.18 (0.75–13.47). 0.116Male
Female
AFP
3.05 (1.42–6.54) 0.004≥400 (ng/ml)
<400 (ng/ml)
HbsAg
1.433 (0.49–4.13) 0.507
Yes/no
GGT(U/I)
2.01 (0.92–4.80) 0.079≥80 IU/l
<80 IU/l
Child–Pugh score
1.09 (0.55–2.13) 0.813
A/B
Tumour size(cm)
1.610 (0.72–3.59) 0.082≥3 cm
<3 cm
Liver-cirrhosis
1.030 (0.73–1.41) 0.864
Yes/no
ALB
3.70 (1.47–9.32) 0.005≥3.5 g/dl
<3.5 g/dl
Pre-NLR
2.40 (1.12–5.16) 0.025 2.34 (1.11–5.12) 0.026≥2
<2
AST
1.20 (0.55–2.60) 0.640≥40 IU/l
<40 IU/l
ALT
1.12 (0.53–2.40) 0.761≥40 IU/l
<40 IU/l
AM
2.16 (1.01–4.61) 0.047 2.15 (1.01–4.60) 0.048≥0.5 cm
<0.5 cm
AFP, alpha-fetoprotein; ALB, serum albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase;
HBeAg, hepatitis B e-antigen; NLR, neutrophil–lymphocyte ratio.
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86.2%, 60.5%, 47.6%, respectively (P = 0.046). The cumulative
recurrence rate was significantly higher in the Group B compared
with Group A during the follow-up period.
Kaplan–Meier analysis and the log-rank test were used to cal-
culate the effect of the different AM on PFS and survival. The
5-year PFS and OS in the group of patients with sufficient AM
were longer than insufficient AM (Fig. 3). The log-rank test
showed that PFS and OS were significantly different between these
two groups (P < 0.05).
Discussion
The appearance of 3D reconstruction greatly helped liver surgery,
which made complicated liver structure visualization and func-
tional liver remnant volume valuation more effective. Tradition-
ally, the 3D reconstruction system provides 3D imaging of liver
structures, detailed volumetric analyses based on portal perfusion
and virtual liver resection. In this study, we assessed the AM using
3D-CT image fusion before and after RFA, which was an attempt
at 3D-CT reconstruction. Recent advances in imaging technology
also made image fusion an effective method to evaluate the AM,
and CT image fusion was performed in side-by-side axial images
to assess AM with 12 patients who developed local tumour pro-
gression.7 However, these processes were performed in a two-
dimensional pattern, which the liver structure visualization did
not reach. Another method used in image fusion is US. The
advantage of CT-US fusion imaging was a real-time search that
assisted the targeting of pellets with needles of the liver. When a
Figure 1 Three-dimensional computed tomography (3D-CT) image fusion of a sufficient ablative margin(transparent display; yellow: tumour;
blue: portal vein; cyan: hepatic veins and inferior caval vein; purple: ablation zone; red: hepatic artery). (a) Two-dimension-CT and
pre-operation 3D-CT reconstruction, the relation of the tumour with the portal vein and hepatic vein was observed, respectively. The location
of the tumour was in VII; (b) post-operative 3D-CT reconstruction, the ablation zone was obviously covering the tumour; (c) fusion image,
the spatial relationship between the index tumour and the ablation zone can be observed, AM was detected in a form in multiplanar, in this
patient, the thinnest AM was 5.3 mm, indicating the tumour was completely ablated with a safe AM
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hepatic lesion was too small or affected by a thick subcutaneous
and lung gas shadow, it would be difficult to detect the lesion
margin using US.14 In our study, fusion of the CT data of the
lesion and ablation zone in the multiplanar mode enabled the
spatial relationship between the lesion and ablation zone to be
observed in virtually all directions. As a result, we could clearly
estimate the thinnest AM.
It takes approximately 15 min for the pre-operative 3D recon-
struction. The 3D reconstruction consisted of the liver paren-
chyma, lesion, vasculature and gall bladder, and if necessary, the
pancreas and spleen were also included. The total time for image
fusion was approximately 30 min. We usually selected the portal
phase and arterial phase of the liver CT as a fuse imagingmodality.
The effect of treatment with RFA was still not sufficiently sat-
isfactory, although ablation therapy could be completely achieved.
Traditionally, some studies considered that surgical resection has
an advantage in OS and disease-free-survival compared with RFA.
However, a study of HCC identified that the effect of RFA were
comparable with surgery resection in HCCs smaller than 2 cm
with a 10-year survival rate of 45% for RFA and 58% for surgical
resection (P = 0.08). However, in a larger HCC, the surgery resec-
tion showed superior results.15 Recently, Hong et al. reported that
RFA is an effective treatment in small HCC (≤4 cm),and exhibited
preserved liver function without differences in OS and disease-
free survival.16 There were many factors that could lead to tumour
recurrence: large tumour size, insufficient margin, absence of
tumour capsule and high serum levels of AFP. Microscopic vas-
cular invasion was positively related to early tumour recurrence
after curative resection.17 For the RFA, the tumour size and AM
were significant risk factors for the recurrence of HCC after RFA;
Figure 2 (a) Two dimension computed tomography (2D-CT) and pre-operation 3D-CT reconstruction. The location of the tumour was in the
caudate lobe, and the tumour was inset in the hepatic veins and the inferior caval vein; (b) post-operative 3D-CT reconstruction, the ablation
zone was obviously large than the tumour, and not only one direction ablation were performed; (c) fusion image of the the tumour was
covered by translucence ablation zone successfully, the spatial relationship between the index tumour and the ablation zone can be
observed, AM was detected form in multiplanar, in this patient, the thinnest AM was 1.8 mm, indicating the tumour was completely ablated,
but 5 mm AM were not obtained
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a margin of at least a 0.5 cm–1.0 cm was considered to be a suf-
ficient safety margin.14 In addition, high baseline alpha-
fetoprotein levels, large vessels close to the lesions (<1 cm from the
main or segmental portal branches) and poor differentiation may
also increase the risk of recurrence.18 Another study19 proposed
the hypothesis that the excessive and rapid heating of a lesion may
result in an unpredicted increase in internal pressure, which was
associated with a higher chance of scattering of cancer cells.
In this study, AM was a significant independent factor linked to
PFS for all cases in ourmultivariate analysis. The 1-, 3-, 5-year RFS
was 87.6%, 63.2%, 50.6% for Group A and 77.2%, 51.5%, 35.6%
for Group B, respectively (P = 0.042); the corresponding OS was
94.3%, 73.8%, 64.6%, and 86.2%, 60.5%, 47.6%, respectively (P =
0.046). The PFS of Group A was significantly higher than Group
B, and the insufficient AM may have predominantly contributed
to this effect. In addition, 33.3% (13/39) of Group B was close to
large vessels, which was higher than 16.7% (6/36) observed in
Group A. When the lesion was close to large vessels, the heat
generated by the radiofrequency would be carried away by the
blood, resulting in a less effective treatment and insufficient AM.
This is known as the ‘heat sink effect.’ In this situation, the region
of coagulated necrosis induced by RFA was limited and not suffi-
cient. To enhance the therapeutic effect of RFA, ethanol injection
was performed prior to RFA, which could enlarge the area of
coagulated necrosis and maintain the rate of the local tumour
recurrence at a low level.20 Indeed, with the 3D visualization of the
lesion and hepatic vessel prior to the operation, we made the
decision of whether an ethanol injection was needed pre-
operation. Furthermore, in the prognostic analysis, we found that
patients with sufficient AM had a longer PFS and survival time,
and patients with insufficient AM had a shorter PFS and survival
time. It is most likely insufficient AM is affecting the recurrence,
thereby affecting the prognosis.
One of the CT image fusions failed, which may be as a result of
not having a sufficient range of contrast-enhanced spiral CT scan-
ning of the post-operative lesion. The system could not perform
image fusion registration from asymmetrical CT. Three patients in
the ablation zone group did not have the lesion completely
covered owing to too large vessels. Because respiratory movement
can cause a displacement and deformation of the liver, CT scan-
ning was usually performed at full inspiration as much as possible.
To reduce error, registration was an effective method that could
make the image fusionmore precise. For further registration accu-
racy, a more advanced fusion system using real-time registration
would be needed to trace the complicated movement of the liver
during respiration. However, this technology is not yet commer-
cially available.
RFA is an experienced technique that is performed according
to the location of the lesion with US guiding. The needle tip may
become unclear when it is several centimetres into the liver. In
particular, after first-time RFA, the ablation zone around the
needle tip became indistinct owing to bubbles, which were pro-
duced by excessive heating. This result made the target lesion
and needle tip unclear. However, a diameter larger than a 3-cm
lesion usually requires more than one RFA, thus, multiple punc-
tures in different positions were performed in the same time
when necessary. In our study, in most of the cases performed
was RFA with multiple punctures at the same time; however, a
few cases were not performed in this manner at the early time
period.
There were some limitations in this study. First, not all of the
HCC lesions were histopathologically confirmed; however, the
clinical criteria confirmed the presence of HCC. Second, the
number of patients in our study was relatively small, and a larger
population and multi-central cooperation may contribute to a
more accurate analysis.
Conclusion
Overall, 3D-CT image fusion is a feasible and effective method
that can play an important role in assessing the AM and predicting
recurrence after RFA.
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Figure 3 Kaplan–Meier prognosis analysis of hepatocellular carci-
noma patients (n = 75) after radiofrequency ablation (RFA) with a
sufficient ablative margin (AM) (n = 36) and insufficient AM (n = 39).
The overall survival (OS) and progression-free survival (PFS) for
patients in the insufficient AM group was significantly lower than that
for patients in the sufficient AM group (P < 0.05)
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